Abstract
Eight of 35 patients with cancer receiving COL-3, a tetracycline derivative with antiangiogenic properties, developed anemia while on treatment. All of these patients were enrolled on an approved Phase I clinical trial at the National Cancer Institute. Three of these patients had bone marrow examinations that revealed ringed sideroblasts. This paper describes these cases. Am. J. Hematol. 67:51-53, 2001. Published 2001 Wiley-Liss, Inc.
Publication types
-
Case Reports
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenocarcinoma, Follicular / complications
-
Adenocarcinoma, Follicular / drug therapy
-
Adult
-
Anemia, Sideroblastic / chemically induced*
-
Antibiotics, Antineoplastic / administration & dosage
-
Antibiotics, Antineoplastic / adverse effects
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Bone Marrow / pathology
-
Female
-
Humans
-
Male
-
Middle Aged
-
Tetracycline / administration & dosage
-
Tetracycline / adverse effects*
-
Tetracyclines
-
Thyroid Neoplasms / complications
-
Thyroid Neoplasms / drug therapy
Substances
-
Antibiotics, Antineoplastic
-
Antineoplastic Agents
-
Tetracyclines
-
tetracycline CMT-3
-
Tetracycline